Literature DB >> 31656992

Vasopressin and Copeptin in health and disease.

Mirjam Christ-Crain1.   

Abstract

Arginine Vasopressin (AVP) and copeptin derive from the same precursor molecule. Due to the equimolar secretion, copeptin responds as rapidly as AVP to osmotic, hemodynamic and unspecific stress-related stimuli and both peptides show a very strong correlation. The physiological functions of AVP are homeostasis of fluid balance, vascular tonus and regulation of the endocrine stress response. In contrast, the exact function of copeptin remains unknown. Since copeptin, in contrast to AVP, can easily be measured with a sandwich immunoassay, its main function so far that it indirectly indicates the amount of AVP in the circulation. Copeptin has emerged as a useful measure in different diseases. On one hand, through its characteristics as a marker of stress, it provides a unique measure of the individual stress burden. As such, it is a prognostic marker in different acute diseases such as ischemic stroke or myocardial infarction. On the other side, it has emerged as a promising marker in the diagnosis of AVP-dependent fluid disorders. Copeptin reliably differentiates various entities of the polyuria polydipsia syndrome; baseline levels >20 pmol/L without prior fluid deprivation identify patients with nephrogenic diabetes insipidus, whereas levels measured upon osmotic stimulation with hypertonic saline or upon non-osmotic stimulation with arginine differentiate primary polydipsia from central diabetes insipidus. In patients with hyponatremia, low levels of copeptin together with low urine osmolality identify patients with primary polydipsia, but copeptin levels overlap in all other causes of hyponatremia, limiting its diagnostic use in hyponatremia. Copeptin has also been put forward as predictive marker for autosomal dominant polycystic kidney disease and for diabetes mellitus, but more studies are needed to confirm these findings.

Entities:  

Keywords:  Arginine Vasopressin; Copeptin; Diabetes insipidus

Mesh:

Substances:

Year:  2019        PMID: 31656992     DOI: 10.1007/s11154-019-09509-9

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  97 in total

1.  A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone.

Authors:  W B SCHWARTZ; W BENNETT; S CURELOP; F C BARTTER
Journal:  Am J Med       Date:  1957-10       Impact factor: 4.965

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

3.  The glycopeptide moiety of vasopressin-neurophysin precursor is neurohypophysial prolactin releasing factor.

Authors:  G Nagy; J J Mulchahey; D G Smyth; J D Neill
Journal:  Biochem Biophys Res Commun       Date:  1988-02-29       Impact factor: 3.575

4.  The structure of the precursor to arginine-vasopressin: a model preprohormone.

Authors:  D Richter; H Schmale
Journal:  Prog Brain Res       Date:  1983       Impact factor: 2.453

Review 5.  Water intake keeps type 2 diabetes away? Focus on copeptin.

Authors:  Giovanna Muscogiuri; Luigi Barrea; Giuseppe Annunziata; Martina Vecchiarini; Francesco Orio; Carolina Di Somma; Annamaria Colao; Silvia Savastano
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

6.  Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Stephan J L Bakker; Eric J van der Jagt; Gerjan Navis; Paul E de Jong; Joachim Struck; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 8.237

7.  Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin.

Authors:  G E Gillies; E A Linton; P J Lowry
Journal:  Nature       Date:  1982-09-23       Impact factor: 49.962

8.  Arginine-initiated release of human growth hormone. Factors modifying the response in normal man.

Authors:  T J Merimee; D Rabinowtitz; S E Fineberg
Journal:  N Engl J Med       Date:  1969-06-26       Impact factor: 91.245

9.  Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA.

Authors:  H Land; M Grez; S Ruppert; H Schmale; M Rehbein; D Richter; G Schütz
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

10.  Vasopressin secretion in primary polydipsia and cranial diabetes insipidus.

Authors:  P H Baylis; M B Gaskill; G L Robertson
Journal:  Q J Med       Date:  1981
View more
  19 in total

1.  Water intake, thirst, and copeptin responses to two dehydrating stimuli in lean men and men with obesity.

Authors:  Douglas C Chang; Adela Penesova; Joy C Bunt; Emma J Stinson; Stavros A Kavouras; Marci E Gluck; Ethan Paddock; Mary Walter; Paolo Piaggi; Jonathan Krakoff
Journal:  Obesity (Silver Spring)       Date:  2022-08-02       Impact factor: 9.298

Review 2.  The role of copeptin in kidney disease.

Authors:  Pedro Iglesias; Ramona A Silvestre; María José Fernández-Reyes; Juan J Díez
Journal:  Endocrine       Date:  2022-10-15       Impact factor: 3.925

Review 3.  Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease.

Authors:  Michele Provenzano; Federica Maritati; Chiara Abenavoli; Claudia Bini; Valeria Corradetti; Gaetano La Manna; Giorgia Comai
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

Review 4.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

Review 5.  Approach to the Patient: Hyponatremia and the Syndrome of Inappropriate Antidiuresis (SIAD).

Authors:  Julie Martin-Grace; Maria Tomkins; Michael W O'Reilly; Chris J Thompson; Mark Sherlock
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

6.  Exercise-induced hypercalcemia and vasopressin-mediated bone resorption.

Authors:  M Senda; T Hamano; N Fujii; T Ito; Y Sakaguchi; I Matsui; Y Isaka; T Moriyama
Journal:  Osteoporos Int       Date:  2021-06-17       Impact factor: 4.507

7.  Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease.

Authors:  Federica Piani; Trenton Reinicke; Yuliya Lytvyn; Isabella Melena; Leif E Lovblom; Vesta Lai; Josephine Tse; Leslie Cham; Andrej Orszag; Bruce A Perkins; David Z I Cherney; Petter Bjornstad
Journal:  J Diabetes Complications       Date:  2020-11-26       Impact factor: 2.852

Review 8.  Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.

Authors:  Kang Fu; Yue Hu; Hui Zhang; Chen Wang; Zongwei Lin; Huixia Lu; Xiaoping Ji
Journal:  Front Cardiovasc Med       Date:  2021-12-14

9.  Circadian Clock Component BMAL1 in the Paraventricular Nucleus Regulates Glucose Metabolism.

Authors:  Masanori Nakata; Parmila Kumari; Rika Kita; Nanako Katsui; Yuriko Takeuchi; Tomoki Kawaguchi; Toshiya Yamazaki; Boyang Zhang; Shigeki Shimba; Toshihiko Yada
Journal:  Nutrients       Date:  2021-12-15       Impact factor: 5.717

10.  Vasopressin but Not Oxytocin Responds to Birth Stress in Infants.

Authors:  Sara Fill Malfertheiner; Evelyn Bataiosu-Zimmer; Holger Michel; Sotirios Fouzas; Luca Bernasconi; Christoph Bührer; Sven Wellmann
Journal:  Front Neurosci       Date:  2021-08-27       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.